Clinical Trial Update: A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma [Phase 2]

View source ↗

Summary

A Phase 2 study of Lebrikizumab for severe asthma dependent on oral corticosteroids has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Lebrikizumab (RO5490255) (Lebrikizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Asthma | Phase 2 | Status: COMPLETED